Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PDC Biotech and Theratechnologies have entered into an exclusive license agreement for Theratechnologies's family of antagonists of the prostaglandin F2 alpha receptor for use in preterm labor and primary dysmenorrhea.
Subscribe to our email newsletter
In June 2006, Theratechnologies had granted an option to licence PDC31 which had shown efficacy in vitro and in animal models in pre-term labor. With this exclusive licence PDC will be developing both an injectable formulation for the treatment of preterm labor and a topical formulation of this compound for the treatment of primary dysmenorrhea.
PDC’s initial focus is to obtain clinical proof-of-concept with the injectable formulation of PDC31 by demonstrating its ability to stop uterine contractions in healthy women with primary dysmenorrhea.
Patricia Griffin, executive vice president and chief development officer of PDC, said: “A positive outcome with an injectable formulation in the planned Phase I/II study would support moving forward with the injectable in preterm labor and with a topical formulation (PDC41) in primary dysmenorrhea.”